(EXEL) Exelixis - Performance 100% in 12m
EXEL performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
54.78%
#6 in Peer-Group
Rel. Strength
93.21%
#505 in Stock-Universe
Total Return 12m
100.00%
#15 in Peer-Group
Total Return 5y
91.44%
#12 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | 19.9 |
| P/E Forward | 21.8 |
| High / Low | USD |
|---|---|
| 52 Week High | 46.26 USD |
| 52 Week Low | 21.96 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 65.51 |
| Buy/Sell Signal +-5 | -0.59 |
| Support / Resistance | Levels |
|---|---|
| Support | 42.6, 36.2, 33.4, 25.8 |
| Resistance |
12m Total Return: EXEL (100%) vs XBI (-7.2%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| GILD NASDAQ Gilead Sciences |
3.11% | 68.3% | 77.5% | 22.7 | 13.6 | 0.23 | 28.3% | -3.71% |
| UTHR NASDAQ United Therapeutics |
-9.3% | -6.89% | 148% | 11.3 | 10.5 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
2.9% | -1.4% | 35.4% | 25.4 | 13.4 | 0.93 | 0.60% | 41% |
| BIM PA Biomerieux |
0.57% | 33% | -5.3% | 33.1 | 25.8 | 1.55 | -38.5% | -25.1% |
| NBIX NASDAQ Neurocrine Biosciences |
3.89% | -5.88% | 1.36% | 43 | 24.8 | 0.27 | 18.7% | -34.3% |
| KMDA NASDAQ Kamada |
12.2% | 59.2% | -5.89% | 25.5 | 22.8 | 0.91 | 48.1% | 3.93% |
| PTCT NASDAQ PTC Therapeutics |
0.66% | 61.7% | -9.1% | 7.71 | 6.26 | 0.81 | - | 68% |
| ERF PA Eurofins Scientific SE |
3.23% | 38.8% | 14.5% | 28.9 | 15.4 | 0.64 | -62.1% | -19.3% |
Performance Comparison: EXEL vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for EXEL
| Total Return (including Dividends) | EXEL | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 3.31% | 4.38% | 4.99% |
| 3 Months | 19.60% | 5.22% | 10.23% |
| 12 Months | 100.00% | -7.16% | 14.42% |
| 5 Years | 91.44% | -24.61% | 110.17% |
| Trend Score (consistency of price movement) | EXEL | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 53% | 3.5% | 79.1% |
| 3 Months | 77.2% | 75.7% | 95.5% |
| 12 Months | 91.8% | -85.1% | 44.7% |
| 5 Years | 40.6% | -52.6% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | %th61.00 | -1.02% | -1.60% |
| 3 Month | %th67.50 | 13.67% | 8.50% |
| 12 Month | %th93.00 | 115.43% | 74.79% |
| 5 Years | %th95.00 | 153.94% | -8.91% |
FAQs
Does Exelixis (EXEL) outperform the market?
Yes,
over the last 12 months EXEL made 100.00%, while its related Sector, the SPDR S&P Biotech (XBI) made -7.16%.
Over the last 3 months EXEL made 19.60%, while XBI made 5.22%.
Performance Comparison EXEL vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
EXEL vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -0.4% | -1.7% | 23.8% | 86% |
| US NASDAQ 100 | QQQ | -0% | -2.1% | 22.3% | 86% |
| German DAX 40 | DAX | 0.6% | 3.9% | 12.2% | 70% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 2.3% | -0.9% | 23.3% | 82% |
| Hongkong Hang Seng | HSI | 1.5% | -3.8% | 5.2% | 63% |
| India NIFTY 50 | INDA | 0.7% | 1.4% | 26.4% | 100% |
| Brasil Bovespa | EWZ | -3.1% | -4.7% | 0.8% | 87% |
EXEL vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -0.4% | -2.4% | 19.5% | 74% |
| Consumer Discretionary | XLY | -1.5% | 0.4% | 30.7% | 81% |
| Consumer Staples | XLP | -0.7% | 3.4% | 24.3% | 90% |
| Energy | XLE | -1.1% | -2.8% | 28.6% | 101% |
| Financial | XLF | -0.6% | -0.3% | 20.6% | 72% |
| Health Care | XLV | 0.7% | 0.8% | 31.3% | 105% |
| Industrial | XLI | -1.3% | -0.9% | 17% | 76% |
| Materials | XLB | -3.5% | -2.5% | 19.6% | 93% |
| Real Estate | XLRE | 0.4% | 2.4% | 25.2% | 87% |
| Technology | XLK | 0.1% | -5.7% | 20.8% | 89% |
| Utilities | XLU | 0.9% | 3.8% | 22.5% | 77% |
| Aerospace & Defense | XAR | -0.6% | -4.2% | 5.4% | 52% |
| Biotech | XBI | -0.1% | -1.1% | 37.9% | 107% |
| Homebuilder | XHB | -5.3% | -8.3% | 29.8% | 94% |
| Retail | XRT | -3.1% | -2.2% | 29% | 90% |
EXEL vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | -1.3% | -5.37% | 32.3% | 107% |
| Natural Gas | UNG | 4.5% | 11.9% | 39.9% | 106% |
| Gold | GLD | 1.1% | 4.1% | 4.5% | 57% |
| Silver | SLV | 1.1% | -1.9% | 7.1% | 77% |
| Copper | CPER | -2.7% | -2.9% | 3.2% | 83% |
EXEL vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | 1.3% | 0.1% | 28.4% | 99% |
| iShares High Yield Corp. Bond | HYG | 1.1% | 1.4% | 25.7% | 89% |